Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis and Erythema Exsudativum Multiforme

  • Sylvia H. KardaunEmail author


In the past, definitions and even the name giving of erythema exsudativum multiforme, Stevens–Johnson syndrome and toxic epidermal necrolysis have been confusing. However, after a consensus classification, which separates erythema exsudativum multiforme from Stevens–Johnson syndrome and toxic epidermal necrolysis, it is now generally accepted that Stevens–Johnson syndrome and toxic epidermal necrolysis are variants within a continuous spectrum of severe, potentially fatal, mucocutaneous adverse drug reactions, whereas erythema exsudativum multiforme is a distinct, generally more mild entity with different clinical signs, mainly precipitated by infections, e.g. herpes simplex virus.


Keratinocyte Epidermis Skin Mucosae Apoptosis Epidermal necrosis Adverse drug reactions Stevens–Johnson syndrome Toxic epidermal necrolysis Erythema exsudativum multiforme 


  1. 1.
    Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau JC, SCAR Study Group, Severe Cutaneous Adverse Reactions. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138:1019–24.CrossRefPubMedGoogle Scholar
  3. 3.
    Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bouwes Bavinck JN, Halevy S, Kardaun S, Sidoroff A, Liss Y, Schumacher M, Roujeau JC. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013;133:1197–204.CrossRefPubMedGoogle Scholar
  4. 4.
    Chung WH, Hung SI. Genetic markers and danger signals in Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergol Int. 2010;59:325–32.CrossRefPubMedGoogle Scholar
  5. 5.
    Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35–44.CrossRefPubMedGoogle Scholar
  6. 6.
    Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149–53.CrossRefPubMedGoogle Scholar
  7. 7.
    Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2007;87:144–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Valeyrie-Allanore L, Wolkenstein P, Brochard L, Ortonne N, Maître B, Revuz J, Bagot M, Roujeau JC. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010;163:847–53.CrossRefPubMedGoogle Scholar
  9. 9.
    Worswick S, Cotliar J. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options. Dermatol Ther. 2011;24:207–18.CrossRefPubMedGoogle Scholar
  10. 10.
    Lamoreux MR, Sternbach MR, Hsu WT. Erythema multiforme. Am Fam Physician. 2006;74:1883–8.PubMedGoogle Scholar

Additional Reading

  1. Litt JZ. Litt’s drug eruption and reaction manual. 21st ed. Boca Raton: CRC Press; 2015. ISBN 9781498709903.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of DermatologyCenter for Blistering Diseases, University Medical Center Groningen, University of GroningenGroningenthe Netherlands

Personalised recommendations